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Sir,
We read with great interest the article by Haug et al (2007) and
must complement them for a nicely written work. We have certain
comments to make about their study.
Colorectal adenomas, the precursors of almost all of the
sporadic colorectal cancer (CRC) could not be included in their
study. The ability of various CRC screening programme (eg,
colonoscopy) in reducing CRC mortality by diagnosing and
removing these premalignant lesions cannot be overemphasised.
It is agreed that the false positives due to these adenomas in the
control group would have contributed to marginal increase in the
specificity of faecal pyruvate kinase type M2 (M2-PK) in their
study (Haug et al, 2007), as rightly mentioned by the authors.
But what about the adenomas that could have been missed out
by performing M2-PK assay in the controls? The prevalence of any
adenomatous lesion in their control group would have been
somewhere around 30% and roughly 8% would have been
advanced adenomas (Anderson et al, 2003), usually described as
villous adenomas, tubular adenomas 410mm, high-grade dys-
plasia, malignant polyp or 43 adenomas (ie, around 73 out of
these 917 control group patients (Haug et al, 2007)). The previous
studies have reported sensitivity of M2-PK to be just 30% in
diagnosing advanced adenomas (Shastri et al, 2006) and 40% by
Koss et al (2005) (only as an abstract). Thus, assuming that a
sensitivity of around 35% for diagnosing these advanced adenomas
from the above two studies would be applied to the population
studied, then there would be a marked decrease in the resulting
sensitivity of M2-PK for diagnosing colorectal neoplasia (CRN),
that is CRC with advanced adenomas. Thus, the estimated
sensitivity of M2-PK in diagnosing CRN would decrease to 48%
(26þ45/73þ74) as against 67% (45/74) reported in this study
(Haug et al, 2007). This would be highly unacceptable for any CRC
screening test and especially for M2-PK with such a poor
specificity of around 80%, which is much lower than that of any
of the faecal screening tests for CRC, in fact even lower than that of
Guaiac-based faecal occult blood test (FOBTs).
One of the limitations of their study was a retrospective study
design with historical controls; these subjects did not undergo either
any of the more accurate faecal screening test, for example, IFOBT
(immunological FOBT) or a colonoscopy for confirming the results of
M2-PK in detecting CRC. Thus, if the prevalence of CRC is taken to
be 1% in the historical controls, there lies a possibility of missing out
significant number of CRC in the control group considering such a
low performance characteristics which is highly unacceptable.
We agree with the authors that the poor performance
characteristics (especially low specificity and poor PPV) of faecal
tumour M2-pyruvate kinase (M2-PK) as has also been reported in
previous prospective study (Shastri and Stein, 2007) does not
warrant its use as a marker for CRC screening. This is particularly
relevant when other better options are available for stool testing
for CRC namely IFOBT (Allison et al, 1996; Morikawa et al, 2005)
and should have been discussed by the authors. These ELISA-
based IFOBTs (Allison et al, 1996) or automatically analysable
IFOBT (Morikawa et al, 2005) have demonstrated sensitivity of
around 60% and specificity of about 90%. Recently various ‘office
based or bedside’ simple, convenient and cheap strip-based IFOBT
have been validated for CRC screening with performance
characteristics similar to that of an ELISA-based IFOBT (Hoepffner
et al, 2006; Smith et al, 2006). In fact our group compared an
office-based IFOBT with that of M2-PK to show that M2-PK and
IFOBT had a sensitivity of 80.4 vs 72.3% for diagnosing CRN,
whereas specificity for these tests were 76.3 vs 94.7%, respectively
(Shastri et al, 2007). All the above information further demon-
strates it emphatically that M2-PK cannot be recommended as a
marker for CRC screening.
Considering above factors it would be really catastrophic to
recommend M2-PK as a biomarker for screening patients with
CRC when much better options for the same are available.
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